Carmelo Tibaldi

2.8k total citations · 1 hit paper
73 papers, 2.1k citations indexed

About

Carmelo Tibaldi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Carmelo Tibaldi has authored 73 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Oncology, 47 papers in Pulmonary and Respiratory Medicine and 23 papers in Molecular Biology. Recurrent topics in Carmelo Tibaldi's work include Lung Cancer Treatments and Mutations (43 papers), Lung Cancer Research Studies (34 papers) and Cancer Treatment and Pharmacology (15 papers). Carmelo Tibaldi is often cited by papers focused on Lung Cancer Treatments and Mutations (43 papers), Lung Cancer Research Studies (34 papers) and Cancer Treatment and Pharmacology (15 papers). Carmelo Tibaldi collaborates with scholars based in Italy, Netherlands and United States. Carmelo Tibaldi's co-authors include Elisa Giovannetti, Alfredo Falcone, Armida D’Incecco, Godefridus J. Peters, Enrico Vasile, Antonio Chella, Federico Cappuzzo, Romano Danesi, Gabriella Fontanini and Editta Baldini and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Cancer.

In The Last Decade

Carmelo Tibaldi

71 papers receiving 2.0k citations

Hit Papers

PD-1 and PD-L1 expression in molecularly selected non-sma... 2014 2026 2018 2022 2014 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
    2014 492 citations Armida D’Incecco, Mariacarla Andreozzi et al. British Journal of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Carmelo Tibaldi Italy 20 1.5k 991 604 351 211 73 2.1k
David F. Heigener Germany 20 1.1k 0.7× 1.0k 1.0× 650 1.1× 349 1.0× 189 0.9× 69 1.9k
Panos Fidias United States 25 1.7k 1.1× 1.8k 1.9× 925 1.5× 276 0.8× 170 0.8× 58 3.0k
Katherine Liau United States 19 1.1k 0.7× 843 0.9× 861 1.4× 441 1.3× 104 0.5× 36 2.0k
Guillermo López-Vivanco Spain 21 1.3k 0.8× 1.0k 1.0× 677 1.1× 405 1.2× 77 0.4× 116 2.1k
Jane Robertson United Kingdom 22 1.3k 0.8× 510 0.5× 816 1.4× 283 0.8× 121 0.6× 57 2.0k
G. Frasci Italy 22 1.3k 0.9× 976 1.0× 400 0.7× 315 0.9× 127 0.6× 97 1.9k
Massimo Lopez Italy 21 1.6k 1.1× 598 0.6× 405 0.7× 516 1.5× 250 1.2× 59 2.2k
Francesco Passiglia Italy 26 1.4k 0.9× 1.2k 1.2× 814 1.3× 629 1.8× 91 0.4× 104 2.4k
Sibyl Anderson United States 19 695 0.5× 1.2k 1.2× 944 1.6× 524 1.5× 92 0.4× 40 2.1k
Giuseppe Lo Russo Italy 24 1.3k 0.8× 731 0.7× 567 0.9× 371 1.1× 232 1.1× 145 2.0k

Countries citing papers authored by Carmelo Tibaldi

Since Specialization
Citations

This map shows the geographic impact of Carmelo Tibaldi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carmelo Tibaldi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carmelo Tibaldi more than expected).

Fields of papers citing papers by Carmelo Tibaldi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carmelo Tibaldi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carmelo Tibaldi. The network helps show where Carmelo Tibaldi may publish in the future.

Co-authorship network of co-authors of Carmelo Tibaldi

This figure shows the co-authorship network connecting the top 25 collaborators of Carmelo Tibaldi. A scholar is included among the top collaborators of Carmelo Tibaldi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carmelo Tibaldi. Carmelo Tibaldi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Camerini, Andrea, Francesca Mazzoni, Vieri Scotti, et al.. (2024). Efficacy and Safety of Chemotherapy after Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Medicine. 13(13). 3642–3642. 3 indexed citations
2.
3.
Honeywell, Richard J., Ietje Kathmann, Elisa Giovannetti, et al.. (2020). Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance. Cancers. 12(11). 3322–3322. 16 indexed citations
4.
Tibaldi, Carmelo, et al.. (2017). Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors. World Journal of Clinical Oncology. 8(4). 320–320. 7 indexed citations
5.
D’Incecco, Armida, Mariacarla Andreozzi, Vienna Ludovini, et al.. (2014). PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. British Journal of Cancer. 112(1). 95–102. 492 indexed citations breakdown →
6.
7.
Tiseo, Marcello, Elisa Giovannetti, Carmelo Tibaldi, et al.. (2012). Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed–carboplatin. Lung Cancer. 78(1). 92–99. 33 indexed citations
8.
Tibaldi, Carmelo, Elisa Giovannetti, Marcello Tiseo, et al.. (2011). Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients. Annals of Oncology. 23(3). 670–677. 45 indexed citations
9.
Honeywell, Richard J., Elisa Giovannetti, Nienke Losekoot, et al.. (2010). Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry. Journal of Chromatography B. 878(15-16). 1059–1068. 83 indexed citations
10.
Tibaldi, Carmelo, et al.. (2009). Cisplatin plus Gemcitabine as Adjuvant Chemotherapy for Radically Resected Non–Small-Cell Lung Cancer: A Pilot Study. Clinical Lung Cancer. 10(1). 53–57. 13 indexed citations
11.
12.
Giovannetti, Elisa, Enrico Vasile, Carmelo Tibaldi, et al.. (2008). Correlation Between Cytidine Deaminase Genotype and Gemcitabine Deamination in Blood Samples. Nucleosides Nucleotides & Nucleic Acids. 27(6-7). 720–725. 53 indexed citations
13.
Vasile, Enrico, Carmelo Tibaldi, Antonio Chella, & Alfredo Falcone. (2008). Erlotinib after Failure of Gefitinib in Patients with Advanced Non-small Cell Lung Cancer Previously Responding to Gefitinib. Journal of Thoracic Oncology. 3(8). 912–914. 30 indexed citations
14.
Lucchi, Marco, Antonio Chella, Franca Melfi, et al.. (2007). Four-Modality Therapy in Malignant Pleural Mesothelioma: A Phase II Study. Journal of Thoracic Oncology. 2(3). 237–242. 20 indexed citations
15.
Tibaldi, Carmelo, Serafino Ricci, Ilaria Bernardini, et al.. (2004). Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the “polmone toscano group” (POLTO). Lung Cancer. 48(1). 121–127. 7 indexed citations
16.
17.
18.
Tibaldi, Carmelo, et al.. (1998). Epirubicin/vinorelbine as first line therapy in metastatic breast cancer. Breast Cancer Research and Treatment. 49(2). 129–134. 19 indexed citations
19.
Baldini, Editta, Carmelo Tibaldi, E. Pfanner, et al.. (1996). Phase II Study of Oral Doxifluridine in Elderly Patients with Advanced Non-Small-Cell Lung Cancer. American Journal of Clinical Oncology. 19(6). 592–594. 9 indexed citations
20.
Baldini, Editta, Carmelo Tibaldi, Antonio Chella, et al.. (1996). Phase II study of vinorelbine/ifosfamide/cisplatin for the treatment of advanced non-small-cell lung cancer. Annals of Oncology. 7(7). 747–749. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David F. Heigener Breakdown of academic impact, for papers by Panos Fidias Breakdown of academic impact, for papers by Katherine Liau Breakdown of academic impact, for papers by Guillermo López-Vivanco Breakdown of academic impact, for papers by Jane Robertson Breakdown of academic impact, for papers by G. Frasci Breakdown of academic impact, for papers by Massimo Lopez Breakdown of academic impact, for papers by Francesco Passiglia Breakdown of academic impact, for papers by Sibyl Anderson Breakdown of academic impact, for papers by Giuseppe Lo Russo
Rankless by CCL
2026